CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Prague, Czech Republic and virtually, from July 1-3, 2022. The presentations are:
- Identification of novel potent oral Factor XIIa inhibitors that block kallikrein kinin system activation in a preclinical model of angioedema: Allen C. Clermont, Director, Preclinical Pharmacology, KalVista Pharmaceuticals, Inc. Results shared as an oral presentation and Q&A on Friday, 1 July 2022 from 16:15 - 17:45 CET in Room E1 and online
- Efficacy of the Oral Plasma Kallikrein Inhibitor, Sebetralstat, by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema: Emel Aygören-Pürsün, MD, Department for Children and Adolescents, University Hospital Frankfurt, Germany. (Abstract/Poster #XXX). Results shared as a flash talk oral poster presentation on Saturday, 2 July 2022 from 10:30 - 12:00 CET in Room D7 and online
- Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor, Sebetralstat, in Adolescent and Adult Patients with Hereditary Angioedema: Phase 3 Study Design: Andrea Zanichelli, MD, Department of Internal Medicine, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco-University of Milan, Italy. e-Poster to be shared online
- Population Pharmacokinetic Analysis of KVD900 in Healthy Adult Volunteers and Patients with Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients: Sinisa Savic, PhD, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. e-Poster to be shared online
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
For more information about KalVista, please visit www.kalvista.com.
For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.
For more information on the KVD824 HAE prophylaxis Phase 2 KOMPLETE study, please visit www.kompletestudy.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for sebetralstat, KVD824 and other candidates in development, the ability of sebetralstat, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
